Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1)

<div>IGF1 treated patients do not show the same decrease in endurance to testing as untreated RTT patients. Endurance refers to the decrease in social/cognitive rating (RSS) from the beginning to the end of each visit (T0 and T1). In untreated patients, there is a significant decrease in scores from the start to the end of testing at T1. In treated patients, such a decrease was not seen following IGF-1 treatment. Recall that an increasing (positive on the graph above) score indicates improvement in social and cognitive ability.</div>

Autism Research and Treatment

fig3

Figure 3

Figure 3: Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1) 

Figure 3 | Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1) 